Could a leukemia drug help fight breast cancer? new trial investigates
NCT ID NCT04113863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a drug called ATRA (all-trans retinoic acid) to the standard hormone therapy anastrozole could shrink tumors more effectively in postmenopausal women with a common type of early breast cancer (HR-positive/HER2-negative). The trial was planned for 76 participants and took place before their scheduled surgery. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Papa Giovanni XXIII
Bergamo, 24127, Italy
-
Ospedale Santa Maria della Misericordia di Udine
Udine, UD, 33100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which CDK4/6 drug is easiest to tolerate in early breast cancer?
- Triple attack on tough breast cancer: combining targeted therapies may improve outcomes
- Could an alcoholism drug plus copper fight breast cancer?
- Breath test could spot breast cancer without needles or scans
- Mind over tumor: short therapy may improve chemo response in breast cancer
- New drug cocktail aims to delay chemo in metastatic breast cancer